Transverse Raises Financing to Support Clinical Development of Point-Guard Device

April 28, 2025—Transverse Medical Inc. announced the completion of a Series B2 financing round of more than $10 million. The Colorado-based early stage medical device company is focused on cerebral embolic protection (CEP) for stroke prevention during transcatheter aortic valve replacement (TAVR) procedures.

According to Transverse Medical, the proceeds from the Series B2 round will support the continuation of the clinical validation of the company’s Point-Guard CEP device in a feasibility clinical study as well as the ongoing development of the Point-Guard platform.

Additionally, the funds will be used to expand operational infrastructure including engineering, regulatory, quality, and operating teams as it advances toward pivotal trials and an FDA investigational device exemption submission.

On April 21, Transverse Medical announced the completion of enrollment of the first series of patients undergoing TAVR in the feasibility study of the Point-Guard device, which is being conducted at the Victorian Heart Hospital in Melbourne, Australia. Study investigator Robert Gooley, MD, commented on the procedures in the company’s press release.

“Point-Guard was easy to use, simple to deploy and retrieve, and was free of adverse events in this first phase of the study,” stated Dr. Gooley. “Positioning the Point-Guard in the arch anatomy was predictable and the asymmetric design of the filter provided a unique approach for complete coverage of all the major arch vessels.”

The company advised that the Point-Guard feasibility study in Australia is being conducted under the Therapeutic Goods Administration’s clinical trial notification scheme and that the device has not been approved for human use by the FDA in the United States.